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HIGHLIGHTS
 First prospective feasibility and safety
clinical trial on unilateral CB resection for
the treatment of high blood pressure.
 In drug-resistant patients with
hypertension, unilateral CB resection
was feasible and safe.
 Unilateral CB resection lowered blood
pressure by 26 mm Hg in 57% of patients
with drug-resistant hypertension
associated with a reduction in muscle
sympathetic nerve activity and its
baroreceptor reﬂex control.
 Whole drug equivalents were reduced in
the responding patients.
 Responding patients had characteristics
distinct to those that did not respond;
these should allow patient selection for
future CB modulation trials.
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SUMMARY
Animal and human data indicate pathological afferent signaling emanating from the carotid body that
drives sympathetically mediated elevations in blood pressure in conditions of hypertension. This ﬁrst-in-man,
proof-of-principle study tested the safety and feasibility of unilateral carotid body resection in 15 patients
with drug-resistant hypertension. The procedure proved to be safe and feasible. Overall, no change in blood
pressure was found. However, 8 patients showed signiﬁcant reductions in ambulatory blood pressure
coinciding with decreases in sympathetic activity. The carotid body may be a novel target for treating an
identiﬁable subpopulation of humans with hypertension. (J Am Coll Cardiol Basic Trans Science 2016;1:313–24)
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
F ound bilaterally at the bifurcation ofthe common carotid artery, the ca-rotid bodies (CBs) are strategically
located to ensure that adequate oxygen is
supplied to the brain. With the highest blood ﬂow
per tissue weight of any organ (1), they are exquisitely
sensitive to small alterations in blood oxygen, carbon
dioxide, pH, and blood ﬂow itself (2,3). Despite their
small size, the CBs exert powerful reﬂex effects on
the respiratory and cardiovascular system (4) that
have been preserved through evolution and are
deemed pivotal for survival (5), perhaps due to their
defensive reﬂex role. This powerful afferent system
normally remains quiescent at sea level in resting
conditions, but during hypoxia, the CBs are activated,
increasing ventilation, increasing sympathetic activ-
ity, inducing alkalosis, and contributing to periodic
breathing during sleep (6,7).
In patients with hypertension, the CBs exhibit both
hyper-reﬂexia and aberrant discharge; in sleep apnea,
the activation of the CBs is, in part, responsible for
the excessive sympathetic activity and hypertension
associated with this condition (8). Moreover, the hy-
pertension evoked in a rat model of sleep apnea (by
chronic intermittent hypoxia), is reliant on afferent
activity generated by the CBs (9), and patients with
hypertension may have exaggerated peripheral che-
moreﬂex sensitivity to hypoxia (10,11). Additionally,
acute reversible inactivation of the CBs, with hyper-
oxia, caused a transient reduction in blood pressure
(BP) and muscle sympathetic nerve activity (MSNA) in
patients with hypertension (12). In rats with hyper-
tension, severing the connection between the CBs
and brain lowered both arterial pressure and sympa-
thetic activity chronically (13). These data point to-
ward the CBs as a therapeutic target to treat
sympathetically mediated diseases (14). The global
clinical problem and ﬁnancial burden of hypertension
continues to escalate (15), and 8% to 14% of the
1 billion patients with hypertension worldwide are
drug resistant or intolerant (16). Therefore, new
approaches for treating drug-resistant hypertension
are justiﬁed, as are studies to identify the targets/
mechanisms driving hypertension. We describe the
ﬁrst prospective proof-of-concept, safety and feasi-
bility study of unilateral (u) CB excision from a
cohort of patients with drug-resistant hypertension.
We report, secondarily, on the proportion of these
patients that showed a response in BP, the hypoxic
ventilatory response (HVR), and MSNA.
METHODS
STUDY DESIGN AND PATIENTS. We present pooled
results from 2 independent centers in which the pri-
mary endpoints were safety and feasibility of uCB
excision in patients with drug-resistant hypertension.
Secondary endpoints were to assess the proportion of
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ABBR EV I A T I ON S
AND ACRONYMS
ABP = ambulatory blood
pressure
ASBP = ambulatory systolic
blood pressure
BRS = baroreceptor reﬂex
sensitivity
CB = carotid body
HRV = heart rate variability
HVR = hypoxic ventilatory
response
MSNA = muscle sympathetic
nerve activity
OBP = ofﬁce blood pressure
OSBP = ofﬁce systolic blood
pressure
uCB = unilateral carotid body
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patients showing reductions in ambulatory blood
pressure (ABP) and MSNA. Inclusion criteria were:
age between 18 to 75 years; taking $3 antihyperten-
sive medications, including a diuretic agent, at
maximal tolerated dose; no evidence of causes of
secondary hypertension following thorough
biochemical, clinical, and imaging assessment
(detailed in Supplemental Table 1); ofﬁce systolic
blood pressures (OSBPs) $150 mm Hg; daytime mean
ABP $135 mm Hg (Table 1, Supplemental Table 2).
There was no control group because this was a
ﬁrst-in-man, safety and feasibility study. Exclusion
criteria are detailed in Supplemental Table 3. A total of
113 patients were recruited from specialist hyperten-
sion clinics at Bristol, United Kingdom; Gdansk,
Poland; and London, United Kingdom. Following
screening in Bristol and Gdansk, 15 patients (7 men
and 8 women) were eligible, including 3 participants
who had undergone renal denervation and 2 with
sleep apnea who were on continuous positive airway
pressure. All patients gave written informed consent.
The study complied with the Declaration of Helsinki,
was approved by the Central Bristol research ethics
committee (12/SW/0277) and the Medical University of
Gdansk Independent Bioethics Commission for
Research (NKBBN/398/2012), and was registered at
ClinicalTrials.gov (NCT01745172 and NCT01729988).
Informed consent was obtained from all patients.
STUDY PROTOCOL. Screening . Screening occurred
44  15 days before the baseline visit. Clinical history,
examination, and blood tests were taken to ensure
that participants met entry criteria (see the previous
text, and Supplemental Table 3). Ofﬁce blood pres-
sure (OBP) and 24-h ambulatory BP monitoring were
recorded; for most patients, the latter commenced
after observing antihypertensive pill administration
(n ¼ 11). A polysomnography study was performed.
Patients were asked to keep a home blood pressure
(HBP) and a medication diary for at least 10 days; this
was the established practice and was a surrogate
marker for drug compliance at the time this study
commenced. Computed tomographic angiography of
the carotid arteries was performed to deﬁne the ca-
rotid anatomy, and to assess the extent of athero-
matous plaque/calciﬁcation, if any, and location of
carotid body as described previously (17). Participants
with high bifurcations, signiﬁcant atheroma, un-
identiﬁable carotid bodies, or carotid bodies inac-
cessible via the lateral surgical approach (see the
following text) were excluded.
Study sess ions . Visits were at baseline (27  11 days
pre-operative) and at 1, 3, 6, and 12 months post-CB
resection. Following this clinical review, a blood
sample (including a full blood count) (Tables 1 and 2)
was taken and OBP, 24h ABP (at 3-, 6-, and 12-month
follow-ups), beat-to-beat BP, MSNA, baroreﬂex
sensitivity (BRS), and HVR were measured. Poly-
somnography was repeated 1 and 3 months after uCB
resection, and HBP and medication diaries were
repeated at 3 months post-operatively.
PROCEDURE. Safety moni tor ing .
1. Adverse event reporting. Adverse events were re-
ported as per local sponsor guidelines, in line with
ICH Good Clinical Practice recommendations,
and were collated by the independent Clinical
Research Organisation monitoring the studies and
reviewed by the Clinical Events Committee formed
by Cibiem.
2. HVR.The HVR was measured before and after uCB
to assess any effect on chemoreﬂex sensitivity.
Using an established poikilocapnic hypoxic pro-
tocol (18), patients were switched from breathing
room air to 100% N2 for up to 10 to 30 s. The
procedure was repeated 5 to 10 times to achieve a
range of SpO2 from 100% to 75% while measuring
respiratory frequency and tidal volume using
spirometry (AD Instruments, Sydney, Australia).
The HVR was calculated by assessing the largest
3 subsequent breaths during/following inhalation
of 100% N2. Minute ventilation was plotted
against the SpO2, and the slope of the regression
reﬂects the HVR.
3. Sleep studies. Sleep data were acquired using
Embla Sleep Systems (Embla Systems Inc., Thorn-
ton, Colorado) and analyzed using REMlogic soft-
ware (Embla Systems Inc.). Post-uCB resection,
sleep studies were performed at 1 and 3 months for
11 patients and at 1 month only for the remaining
patients. The sleep studies were scored by an in-
dependent single scoring specialist center using
international guidelines from the American Acad-
emy of Sleep Medicine (19).
4. Medications. Patients’ antihypertensive medicines
were maintained at baseline values to minimize
the effect of medication changes on BP after uCB
unless there were strong clinical grounds for the
management of symptomatic hypotension or other
adverse events.
BP monitor ing . OBP was taken in the sitting posi-
tion using an automatic oscillometric monitor (Omron
705IT, Omron Healthcare Europe, Hoofddorp, the
Netherlands). BP was measured according to
protocol-speciﬁed guidelines on the basis of the
European Society of Hypertension recommendations
(20) and National Institute for Health and Care Excel-
lence guidelines. The 24-h ABP (Spacelabs Healthcare,
Snoqualmie, Washington) data was acquired at least
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once hourly during sleep and twice hourly during the
day (night: 12:00 AM to 5:59 AM; day: 6:00 AM to 11:59
PM). The HBP (Omron 705IT) was averaged across
the last 2 of 3 morning and 3 evening readings daily
for 10 to 14 days; a medication diary was kept with
HBP readings.
Microneurography and hemodynamic recordings.
During each study visit, continuous BP recordings
were measured using a Finometer (Finapres Medical
Systems, Amsterdam-Zuidoost, the Netherlands),
which was calibrated to the BP measured in the
same arm using an automated cuff, and a 3-lead
electrocardiograph was used for continuous moni-
toring of heart rate; these recordings were used to
calculate BRS. Multiunit MSNA was recorded by
microneurography in the peroneal nerve at the ﬁbular
head (21) using tungsten microelectrodes (FHC Inc.,
Bowdoin, Maine). Heart rate, BP, and MSNA were
measured and recorded continuously using a data
acquisition program (LabChart, AD Instruments).
Following insertion of the microelectrode, resting
hemodynamics and MSNA recordings were collected
TABLE 1 Demographics, Screening Visit, Baseline, Number of Follow-Up Medications, Hemodynamic, and Respiratory Data
Screening Baseline 1 Month 3 Months 6 Months 12 Months
Male/female 7/8 (15) — — — — —
Age, yrs 52  1 — — — — —
Height, m 1.69  0.02 — — — — —
Weight, kg 88.5  4.1 — — — — —
BMI, kg/m2 31.0  1.2 — — — — —
Number of drugs 5.7  0.6 5.7  0.6 5.1  0.5 5.1  0.4 4.9  0.4 5.1  0.5
Ofﬁce
SBP, mm Hg 180  6 168  7 146  8 153  9 158  8 162  10
DBP, mm Hg 106  4 101  5 90  6 95  6 96  6 98  5
MAP, mm Hg 130  4 123  5 108  6 114  6 117  5 119  5
PP, mm Hg 74  8 67  8 57  9 59  11 63  8 63  10
HR, beats/min 75  4 67  4 69  4 70  5 69  3 68  3
Ambulatory day
SBP, mm Hg 167  4 — — 159  6 158  7 167  7
DBP, mm Hg 100  4 — — 95  5 97  6 100  6
MAP, mm Hg 122  4 — — 117  5 117  5 122  4
PP, mm Hg 63  6 — — 64  4 63  3 67  3
Ambulatory night
SBP, mm Hg 145  4 — — 138  5 144  6 138  4
DBP, mm Hg 83  3 — — 81  4 84  5 79  3
MAP, mm Hg 104  3 — — 100  4 104  4 98  4
PP, mm Hg 63  6 — — 64  4 63  3 67  3
Ambulatory overall
SBP, mm Hg 163  4 — — 157  5 156  7 163  7
DBP, mm Hg 97  4 — — 93  4 95  5 97  6
MAP, mm Hg 119  4 — — 115  5 115  6 119  6
PP, mm Hg 67  3 — — 62  4 63  3 67  3
MSNA incidence, per 100 heart beats 77.2  4.0 — — 75.7  3.9 73.1  4.2 72.4  3.5
MSNA frequency, per min — 50.8  2.1 — 49.4  3.1 49.1  1.8 46.3  2.6
BRS, %$s/mm Hg — 1.16  0.26 — 1.21  0.2 1.73  0.19 1.54  0.26
HRV, LF:HF — 2.1  0.5 — 2.2  0.6 1.4  0.3 2.0  0.4
HVR, l/min/SpO2 — 0.44  0.04 0.43  0.07 0.39  0.11 0.56  0.13 0.41  0.06
Respiratory rate, per min — 15.5  1.4 — 15.2  1.0 16.6  1.4 16.4  0.9
Tidal volume, l — 0.63  0.06 — 0.63  0.09 0.59  0.04 0.58  0.05
Minute ventilation, l/min — 8.9  0.8 — 8.5  0.6 9.3  0.7 9.1  0.7
Hb, g/dl — 14.2  0.3 14.1  0.3 14.1  0.4 14.3  0.3 14.2  0.4
HbA1C (DCCT), % — 5.9  0.2 5.8  0.2 6.0  0.2 5.8  0.2 5.7  0.2
Values are n/n (N) or mean  SEM.
BMI ¼ body mass index; BRS ¼ baroreceptor reﬂex sensitivity of muscle sympathetic nerve activity; DBP ¼ diastolic blood pressure; DCCT ¼ Diabetes Control and Com-
plications Trial; Hb ¼ hemoglobin; HbA1C ¼ glycated hemoglobin; HF ¼ high frequency; HR ¼ heart rate; HRV ¼ heart rate variability; HVR ¼ hypoxic ventilatory response; LF ¼
low frequency; MAP ¼ mean arterial pressure; MSNA ¼ muscle sympathetic nerve activity; PP ¼ pulse pressure; SBP ¼ systolic blood pressure; TV ¼ tidal volume.
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over 5 to 20 min of quiet supine rest. Bursts were
identiﬁed, and their frequency (Hz) and incidence
(per 100 heart beats) were measured. Heart rate vari-
ability (HRV) was calculated using an add-on in Lab-
Chart (AD Instruments) using spectral analysis
conforming to previous guidelines (22), with
high from 0.15 to 0.4 Hz, low frequency from
0.04 to 0.15 Hz, and very low frequency from
0.0033 to 0.04 Hz.
BRS measurement on the basis of MSNA burst area.
Ofﬂine, MSNA was normalized to the amplitude of the
largest burst in the recording and was represented as
a percentage of this burst. For each cardiac cycle, the
associated diastolic blood pressure (DBP) was deter-
mined and collected into 1-mm Hg bins. The peak,
beginning, and end of every MSNA burst were marked
in data acquisition software (Spike2, Cambridge
Electronic Design, Cambridge, United Kingdom). The
area of the burst was calculated as the integral of
MSNA between the beginning and end of the burst
(units of % $ s). Each cardiac cycle was associated with
the accompanying MSNA burst area (MSNA burst
area ¼ 0 AU if no burst occurred in that cycle). The
lowest DBP in each cardiac cycle was recorded to
the nearest mm Hg, and the MSNA burst area was
correlated with the DBP of each cardiac cycle over
the entire range of DBPs obtained in each subject.
The spontaneous MSNA BRS was calculated using
DBP and a similar calculation to that described pre-
viously (23).
SURGERY. The surgical removal of the CB was per-
formed following the procedure described by Winter
(24). Under either general or local anesthesia with
sedation, an incision was made over the anterior
aspect of the sternocleidomastoid muscle, one-third
of the distance between the angle of the mandible
and the clavicle, and over the region of the carotid
bifurcation as identiﬁed via ultrasound/computed
tomography angiography. The sternocleidomastoid
muscle was retracted laterally along with the internal
jugular vein to expose the carotid bifurcation. By
gentle retraction of the external carotid artery (in
some cases, the superior thyroid artery was cut to
enhance retraction), the intercarotid septum was
exposed. Tissue within this septum was isolated from
the internal and external carotid arteries, and a liga-
ture was placed at the saddle of the bifurcation. The
septal tissue was excised as close to the ligature as
possible. The surgeries in some cases involved liga-
ture of the pedicle, and in others cautery over the
saddle.
HISTOLOGY. Resected tissue was ﬁxed with 10%
formalin, embedded in parafﬁn, sectioned (50- to
100-mm thick), and stained with hematoxylin and
eosin. The presence of glomus cells and organ mar-
gins were checked and photomicrographs were taken.
ANALYTICAL METHODS AND STATISTICAL ANALYSIS.
All analyses were conducted blind with respect to the
sequence of visits and whether the patient was a BP
responder or nonresponder (see the following text).
All measurements of MSNA burst area and BRS
were calculated by importing acquired data into
MATLAB 8.0 (2012b, The MathWorks, Natick, Massa-
chusetts), and statistical tests of these measures were
TABLE 2 Demographics and Screening Visit Data for Responders
and Nonresponders
Responders Nonresponders p Value
Male/female 3/5 4/2
Age, yrs 55  2 52  3 0.34
Height, m 1.68  0.03 1.72  0.03 0.40
Weight, kg 89.2  5.8 91.1  6.4 0.83
BMI, kg/m2 31.6  1.8 30.9  1.6 0.78
Antihypertensive drugs 5.8  0.5 5.7  0.6 0.94
Ofﬁce screening
SBP, mm Hg 187  11 170  7 0.68
DBP, mm Hg 94  6 107  9 0.26
MAP, mm Hg 118  8 128  8 0.36
PP, mm Hg 70  8 64  4 0.54
HR, beats/min 75  6 72  6 0.75
Ambulatory screening day
SBP, mm Hg 171  8 162  5 0.39
DBP, mm Hg 101  7 98  7 0.27
MAP, mm Hg 124  7 119  6 0.57
PP, mm Hg 71  4 64  4 0.30
Ambulatory screening night
SBP, mm Hg 148  7 143  2 0.56
DBP, mm Hg 83  5 84  4 0.85
MAP, mm Hg 105  5 104  3 0.90
PP, mm Hg 65  6 59  4 0.44
Ambulatory screening overall
SBP, mm Hg 167  7 158  3 0.32
DBP, mm Hg 97  6 95  6 0.84
MAP, mm Hg 120  6 116  5 0.71
PP, mm Hg 70  4 63  4 0.28
MSNA incidence, per 100 heart beats 82.5  4.9 74.1  6.4 0.31
MSNA frequency, per min 51.7  2.9 47.7  4.7 0.46
BRS, %$s/mm Hg 1.23  0.24 1.15  0.59 0.89
HRV, LF:HF 2.5  0.8 2.0  0.7 0.66
HVR, l/min/%SpO2 0.50  0.05 0.32  0.06 0.027
Respiratory rate, per min 18.2  2.0 11.8  1.1 0.025
Tidal volume, l 0.50  0.05 0.84  0.09 0.003
Minute ventilation, l/min 8.9  1.2 9.2  1.2 0.87
HbA1C (DCCT), % 5.99  0.27 5.70  0.16 0.41
Hb, g/dl 14.40  0.43 14.48  0.29 0.89
Values are n or mean  SEM. All variables passed normality except day ambulatory SBP. The
median (ﬁrst quartile, third quartile) were ambulatory systolic blood pressure (p ¼ 0.834):
responders ¼ 169.5 (156.2, 173.7) and nonresponders ¼ 162.3 (152.9, 172.5).
Abbreviations as in Table 1.
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conducted in Prism version 2.0 (GraphPad Software,
Inc., La Jolla, California). Results are presented as
mean  SEM. A 2-sided probability value of p < 0.05
was considered statistically signiﬁcant. Statistical
comparisons of groups were assessed by 1-way anal-
ysis of variance (ANOVA) for parametric data or
Kruskal-Wallis ANOVA on ranks for data that were not
normally distributed. A 2-way ANOVA with Sidak
(between groups) and Tukey (within groups) post
hoc tests was conducted to compare data across
and within groups at different follow-ups. Serial
within-group comparisons were subjected to repeated
measures ANOVA. All variables analyzed with ANOVA
passed the D’Agostino & Pearson normality test and
also Bartlett’s test for equal variance. All variables
passed normality except for day ambulatory systolic
blood pressure (ASBP), which was analyzed with
Kruskal-Wallis test and expressed as median (ﬁrst
quartile, third quartile). Medications were calculated
as a percentage of the maximal recommended dose for
hypertension. For each patient, the whole drug
equivalents (sum of the percentage of the maximal
recommended dose) were calculated on the basis of
doses quoted in the British National Formulary.
RESULTS
SAFETY. There were 2 serious adverse events con-
sisting of prolonged hospitalization of patients with
BP that was difﬁcult to control. One of the events
occurred shortly after the CB removal procedure, and
this event was judged by the Clinical Events Com-
mittee (CEC) to be “possibly related” to the unilateral
removal of the CB. In the other patient, multiple
hospitalizations occurred for BP control before and
after uCB removal, and the hospitalizations bore no
consistent temporal relationship to the CB removal.
These hospitalizations were, therefore, judged by the
CEC to be “unrelated” or “unlikely to be related” to
the uCB.
In 1 patient with pre-existing moderate obstruc-
tive sleep apnea (OSA), sleep-disordered breathing
(SDB) worsened after uCB. This was not noted as an
adverse event by the study site. The CEC felt,
however, that given that SDB was a pre-existing
disease in this patient and the apnea-hypopnea
index increased from 20 events/h at baseline to 74
events/h 3 months post-carotid body removal,
worsening SDB should be noted as an adverse
event. The patient was treated with continuous
positive airway pressure, and the apnea-hypopnea
index decreased substantially. The adverse events
and polysomnography are shown in Supplemental
Tables 4 and 5, respectively.
Patients maintained their ventilatory response to
hypoxia as the average baseline HVR (0.4 
0.1 l/min/% SpO2) (Table 1) was not changed after uCB
resection at any time point. There were no changes
in breathing patterns during sleep after uCB
(Supplemental Table 5), and although blood oxygen
fell to lower minimal levels during desaturation epi-
sodes (from 87  1% to 81  1%; p < 0.05), there were
no changes in the apnea-hypopnea index, apnea
duration, baseline blood oxygen saturation, and
average blood desaturation (Supplemental Table 5).
FEASIBILITY. On the basis of its visualization on
computed tomography scans (Figure 1), a CB was
resected from either the right (n ¼ 11) or left side
(n ¼ 4). Characteristic glomus tissue was found sub-
sequently in histological sections of the resected
specimen in all (Figure 1) but 1 patient; in this patient
we observed no adverse effects, changes in BP, or
changes in any of the other measured variables at all
follow-up visits.
BP, MEDICATION, AND AUTONOMIC INDEXES IN ALL
PATIENTS (N[15). There was no signiﬁcant change
in either ASBP or OSBP at any time following uCB
resection compared with the corresponding values at
screening and baseline (Figure 2, Table 1) (n ¼ 15); a
similar ﬁnding was observed for HBP (Supplemental
Figure 1). Notably, at all follow-up examinations
there was no statistically signiﬁcant difference be-
tween screening and baseline OSBP or 24-h ASBP
(Table 1), indicating stability of BP in the run-up to
uCB resection. Also, there were no changes in MSNA
(frequency or incidence), BRS, heart rate variability,
HVR and minute ventilation (Table 1), or medication
between screening and baseline (Supplemental
Table 2). We next determined if there was a propor-
tion of patients that showed a reduction in BP and
whether this correlated with any other measured
variable.
PROPORTIONATING AND CHARACTERIZING
RESPONDING PATIENTS. We deﬁned a responder as
a participant with evidence of glomus cells in the
resected tissue (as determined histologically) and
a $10-mm Hg drop in ABP at the 3-month follow-up
visit to allow time for patient recovery and the reso-
lution of adverse events. A nonresponder was deﬁned
as having evidence of glomus cells in the resected
tissue, but did not show a $10-mm Hg fall in ambu-
latory BP at 3-month follow-up. On the basis of these
deﬁnitions, there were 8 responders (i.e., 53.3%;
95% conﬁdence interval: 26.6% to 78.7%) who
showed signiﬁcant reductions in ASBP at 3 months
and 6 nonresponders (Figure 3); glomus cells were not
found in 1 patient (see the previous text). No patient
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with a left CB resected and/or prior renal nerve
denervation responded. In the 8 responders, day
ASBP decreased at the 3-month (23  3 mm Hg;
p ¼ 0.0005), 6-month (26  4 mm Hg; p ¼ 0.0021),
but not 12-month (12  8 mm Hg; p ¼ 0.22) follow-up
compared with screening (Figure 3A). Night-time
ASBP was also reduced at 3-month (20  4 mm Hg;
p < 0.0243), 6-month (16  5 mm Hg; p < 0.047) and
at 12-month follow-ups (15  6 mm Hg; although
p ¼ 0.067) compared with screening (Figure 3B) with
24-h ASBP following a similar time-course (Figure 3C).
Comparing both day and night ASBP between re-
sponders and nonresponders, there were signiﬁcant
differences between patient groups at all time points
(Figures 3A and 3B) (p < 0.05 to p < 0.01). Regarding
OSBP, responding patients exhibited a reduction at
1 month (52  8 mm Hg; p ¼ 0.006), 3 months (46 
8 mm Hg; p < 0.005), and 6 months (35  7 mm Hg;
p < 0.0088), but not at 12 months compared with
both screening and baseline (Figure 3D). There was
no change in the variability of ASBP. For ASBP and
OSBP, there were no sex-related differences (Fisher
exact test). The HBP was also reduced in responders
but not nonresponders at 3 months (Supplemental
Figure 1).
ANTIHYPERTENSIVE MEDICATIONS. Among responders,
across all study time points, there was a signiﬁ-
cant difference in whole-dose equivalents (WDE)
(p ¼ 0.0009; 4.5  0.6 WDE at screening and baseline,
falling to 3.5  0.6 WDE by 6 and 12 months). There
was also a trend toward reductions in both the num-
ber of medications (p ¼ 0.06) and medication classes
(p ¼ 0.06). The were no changes in WDE (0.98), the
number of medications (p ¼ 0.15), or medication
classes (p ¼ 0.15), among nonresponders.
MSNA FOLLOWING CB RESECTION. Neither baseline
MSNA burst frequency nor incidence differed
between responders and nonresponders (Table 2,
Figures 4A and 4B) (p¼0.31 and p¼0.46, respectively).
However, compared with baseline, responders
exhibited a decrease in total MSNA burst area/min
at 3 months (374  102%$s/min; p ¼ 0.0137) and
6 months (520  135%$s/min; p ¼ 0.0296), but not
at the 12-month follow-up (p ¼ 0.74) (Figure 4C).
Furthermore, total MSNA burst area/min in the re-
sponders was lower than in nonresponders at 3-month
(374 108%$s/min vs. 281 174%$s/min; p<0.0154),
6-month (165  135%$s/min vs. 16  193%$s/min;
p < 0.025) and at 12-month follow-up (166 
38%$s/min vs. 386 123%$s/min; p¼ 0.06) (Figure 4C).
In contrast, total MSNA burst area/min compared with
baseline did not change at any follow-up time in the
nonresponders (Figure 4C).
BAROREFLEX MODULATION OF MSNA. In responders,
BRS improved as revealed by a decrease at 6-month
(1.50  0.18%$s/mm Hg; p < 0.0245), but not at
12-month follow-up (0.96  0.63%$s/mm Hg;
FIGURE 1 Conﬁrmation of the CB in Resected Tissue
(A) Computed tomography scan of a patient at the level of the carotid bifurcation. Inset is magniﬁed image showing the internal (Int)
and external (Ext) carotid arteries and the carotid bod (CB) (arrows). (B) 3-dimensional reconstruction of the carotid artery bifurcation
from computed tomography images showing the precise position of the CB. This CB was surgically resected (C), and histologically
conﬁrmed by identiﬁcation of densely packed glomus cells and the lateral margin of the CB (Di). (Dii) A high power magniﬁcation of
the boxed area in Di depicting glomus cells. All images are from the same patient. The scans in this image have been enhanced for
contrast/sharpness.
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p ¼ 0.52) compared with baseline (Figure 4D). There
was no change in BRS relative to baseline in non-
responders at any time point (Figure 4D) (p > 0.05).
CHARACTERISTIC DISTINCTIONS BETWEEN RESPONDERS
AND NONRESPONDERS. Before surgery and compared
with nonresponders, responders had a higher hypoxic
ventilatory response (p < 0.027) and faster ventila-
tory frequency (p < 0.025) (Table 2) at baseline
consistent with higher peripheral chemoreﬂex
sensitivity and drive, respectively. Moreover, they
consistently had the right carotid body removed.
DISCUSSION
The present ﬁrst-in-man, proof-of-principle study
was concerned with investigating the safety and
feasibility of unilateral surgical resection of CB as a
therapy in patients with drug-resistant hyperten-
sion. We found that this procedure was safe as
evidenced by an absence of persistent serious
adverse events, maintenance of a ventilatory
response to hypoxia, and with 1 exception, no major
alteration in SDB. With the ﬁnding of glomus cells
in resected tissue from 14 of 15 patients in our
study, the feasibility of the surgical approach has
been demonstrated.
As recently reviewed, CB resection (unilateral and
bilateral) has been performed historically for the
treatment of dyspnea in patients with asthma and
chronic obstructive pulmonary disease (14). In 1 of
these studies, a chronic reduction in BP was noted in
patients who had hypertension, which was main-
tained for 6 months when the study ended; there
was no BP change in the normotensive group (25).
FIGURE 2 Blood Pressure Responses in the Total Cohort Before and After uCB Resection (n¼15)
Ambulatory systolic blood pressure (ASBP), (A) day, (B) night, and (C) 24 h, at screening and at 3-, 6-, and 12-month follow-ups. (D) Ofﬁce
systolic blood pressure (OSBP) at screening, baseline, and at 1-, 3-, 6-, and 12-month follow-ups. The 1-way repeated measures analysis of
variance with Tukey test for multiple comparisons was used. Night: 12:00 AM to 5:59 AM; day: 6:00 AM to 11:59 PM. *p ¼ 0.038; **p ¼ 0.007;
†p ¼ 0.0298. ABP ¼ ambulatory blood pressure monitor; BL ¼ baseline; M ¼ month; Scrn ¼ screening.
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Additionally, a retrospective study showed BP
reduction in patients with hypertension following
uCB tumor resection (26). Although we saw a wors-
ening of SDB in 1 patient with pre-existing OSA, a
systematic analysis of sleep studies in the other pa-
tients in this study and in other studies in which the
CB was denervated/removed (27) has not demon-
strated any consistent change in the severity of OSA.
The causes of OSA are likely to be multifactorial, and
for a given patient, the functional role of the CB in
inducing or preventing OSA episodes may depend on
the precise etiology of the apnea.
CB DYSFUNCTION PREVALENCE IN HYPERTENSION.
Across all patients, there were no changes in ABP or
OBP after uCB resection. This was not surprising given
that hypertension has a heterogeneous etiology and
chemoreﬂex hyper-reﬂexia was reported in only a
subset of patients with cardiovascular disease (18).
Hence, we performed a post hoc analysis using a BP
reduction of >10 mm Hg in daytime ASBP at 3 months
post-uCB resection to identify if a proportion of par-
ticipants had responded, and if so, whether they
exhibited any distinct physiological features. We
found a substantial reduction in daytime ASBP in 8
patients (>20 mm Hg) that persisted for at least 6
months. The BP response after uCB resection wanes at
12 months, which may reﬂect compensation including
that from the other CB. Notably, the level of BP in
responders remained signiﬁcantly lower relative to
nonresponders at 12 months. It is encouraging that in
these responding patients, medications were reduced
compared with baseline, which may have blunted
the magnitude of the BP response. Longer-term
follow-up data is now crucial to determine the
persistence of the BP-lowering effect following uCB
resection. Nevertheless, the reduction in both ABP
and medication suggests that CB modulation therapy
may go beyond a pharmacological treatment for a
subset of patients.
MECHANISM OF ACTION OF CB RESECTION. In the
responders (but not the nonresponders), MSNA total
activity was reduced over a similar time course to the
ABP, indicating reduced vasomotor tone; this is
consistent with data from hypertensive rats (13) and
data seen transiently using hyperoxia to inhibit CB
afferent activity in humans with hypertension (12).
We also noted an improvement in MSNA BRS in the
responder but not in the nonresponder patients,
which could contribute mechanistically to the
lowering of BP. This ﬁnding is consistent with the
known antagonism between peripheral chemore-
ceptor and baroreﬂex function (10).
FIGURE 3 Blood Pressure Data for Responders (n ¼ 8) and Nonresponders (n ¼ 6) as Deﬁned by $10 mm Hg Reduction in ABP at 3-Month Follow-Up
ASBP during day (A), night (B), and 24-h average (C) at 3-, 6-, and 12-month follow-ups (represented as change from screening). (D) OSBP response at screening,
baseline, and at 1-, 3-, 6-, and 12-month follow-ups (represented as change from screening). Two-way repeated measures analysis of variance was used (within groups
*p < 0.05, **p < 0.01, ***p < 0.001; between groups †p < 0.05, ††p < 0.01, †††p < 0.01). Abbreviations as in Figure 2.
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The elevated HVR and higher respiratory fre-
quency in the responders versus nonresponders is
supportive of aberrant hyper-reﬂexia and high CB
drive, respectively. The elevated HVR is consistent
with peripheral chemoreceptor hyper-reﬂexia in hy-
pertension, as reported in animals (13) and humans
with hypertension (8,11). It may be possible to use
HVR and respiratory frequency (and hyperoxia to
depress the CB) (12) to pre-select the patients with
hypertension who are most likely to beneﬁt from CB
modulation therapy, assuming that their arteries and
arterioles are able to vasorelax.
STUDY LIMITATIONS. As a ﬁrst-in-man, safety and
feasibility study, we did not include a control group.
However, in the 1 patient in whom we found no evi-
dence of glomus cells in the resected tissue, we failed
to see a fall in BP. Notwithstanding the recruitment
difﬁculties associated with a surgical intervention,
we acknowledge that the absence of a control arm and
the low number of patients are limitations of the
present study. A percutaneous catheter-based
approach to ablate the CB selectively may be better
tolerated, for example.
Although patients were fully assessed in specialist
hypertension clinics before study entry, drug non-
adherence cannot be ruled out. Notably, we fully
adhered to the established drug adherence pro-
cedures at the time the study was initiated (see
the Methods sections). There were no statistical
differences between screening and baseline OSBP,
which may partly overcome concerns regarding a
Hawthorne effect and regression to the mean.
Comparing total MSNA from the same patient at
different times can be problematic, but we controlled
for this by referencing to the largest burst in the
neurogram.
REASONS FOR DYSFUNCTIONAL CB. The issue of
why the CB develops hypersensitivity is unclear, but
may include hypoperfusion as suggested in heart
failure (2). In the hypertensive condition, this may be
a result of stenosis caused by atheroma or arteriole
hypertrophy; the latter may be induced by elevated
sympathetic activity to the CB and/or angiotensin II.
Inﬂammation is also present in the CB of hyperten-
sive rats (28) and may trigger release of cytokines,
chemokines, and reactive oxygen species that could
FIGURE 4 Sympathetic Activity and its Baroreﬂex Control After uCB Resection
Representative raw muscle sympathetic nerve activity (MSNA) for a responder (A1) and nonresponder (A2) at baseline (left trace) and 6-month
follow-up (right trace). (B) There was no difference in MSNA burst incidence between responders and nonresponders. However, MSNA area
was reduced after uCB resection in the responders but not nonresponders (C), and spontaneous MSNA area baroreﬂex gain improved in re-
sponders but not in nonresponders (D). Two-way repeated measures analysis of variance was used (within groups *p < 0.05; between groups
†p < 0.05); bursts/100HB ¼ bursts per 100 heart beats; other abbreviations as in Figure 2.
Narkiewicz et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 5 , 2 0 1 6
Carotid Chemoreceptors and Human Hypertension A U G U S T 2 0 1 6 : 3 1 3 – 2 4
322
also contribute to its hyperactive state. In rodents
subjected to chronic intermittent hypoxia, a condi-
tion causing hypertension and reﬂected in humans
with sleep apnea, there is a change in the balance of
gasotransmitters including H2S and CO (29) and
purinergic mechanisms (30); whether these occur in
the CBs of human patients with hypertension is
unknown.
Turning to the nonresponders, there are several
explanations for lack of BP improvement. Anatom-
ical variations in the distribution of the CB may
result in insufﬁcient glomus tissue being resected.
We acknowledge the heterogeneous etiology of hy-
pertension and would not expect a BP response
in individuals with nondysfunctional CBs or mech-
anisms unrelated to CB dysfunction. Even in pa-
tients with CB dysfunction, it may be that the
contralateral CB predominates in driving up BP. We
do not rule out stiffened arteries that are unable to
regain compliance even with a reduction in sympa-
thetic tone.
CONCLUSIONS
This is the ﬁrst study that places CB hyper-reﬂexia in
context of a disease state in humans and demon-
strates the potential beneﬁt of modifying that
activity.
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